QLT, Ciba Vision seek to expand drug's patient base
Article Abstract:
QLT Inc. and Ciba Vision Corp. are seeking to expand the patient base of their Visudyne therapy to treat other eye diseases. The firms said that they asked the US Food and Drug Administration (FDA) to give their application a faster-than-usual priority review because there is now no satisfactory treatment for these conditions. The priority designation generally means the FDA will decide whether to approve the use of the drug within six months instead of a year. Visudyne is injected into a patient's arm, then activated by shining a laser into the eye. The drug has been approved for commercial use in 22 countries this year to treat the severe form of age-related macular degeneration (AMD), a leading cause of blindness in people over 50. Some analysts have estimated that Visudyne has a market potential in a few years of US$800-million for the treatment of AMD.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
QLT seeks approval for vision drug in EU
Article Abstract:
Vancouver, Canada-based QLT PhotoTherapeutics Inc, along with partner Ciba Vision Corp, is seeking approval from the 15-member European Union to market Visudyne, a treatment to stabilize vision loss and prevent blindness in people over the age of 50. The photodynamic therapy utilizes a laser light to activate drugs to treat age-related muscular degeneration. QLT and Ciba Vision will seek similar approval in Switzerland and the US.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
imex launches first trial of flagship cancer drug
Article Abstract:
Inex Pharmaceuticals Inc. (Vancouver) is expanding the clinical development of its flagship cancer drug with the launch of the first of three new human trials. The biotechnology firm said it has begun a Phase II study with its Onco TCS drug to treat patients with small-cell lung cancer at two medical centers in Arizona.
Publication Name: Globe & Mail (Toronto, Canada)
Subject: News, opinion and commentary
ISSN: 0319-0714
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Glaxo seeks flu drug approval. QLT shares rise on drug price tag
- Abstracts: Tobacco companies warn of bankruptcy. FDA approves drug to combat anthrax. Boston opens $390M tunnel to send sewage into Atlantic
- Abstracts: Mind over natter. The case for kissing cousins. The truth is out there
- Abstracts: When VC stands for 'very crafty'. Philips seeks hero product to court USA. Project turns airplanes into metro-area satellites
- Abstracts: How to flag a heated debate. Novel approach